<DOC>
	<DOC>NCT00279721</DOC>
	<brief_summary>Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.</brief_summary>
	<brief_title>Phase II Study of IMRT With SIB as Adjuvant Treatment for High Risk Resected Well-differentiated Thyroid Cancer.</brief_title>
	<detailed_description>Resected well-differentiated thyroid neoplasms with at least one high risk feature will receive adjuvant radiation using IMRT with SIB. The acute toxicity and locoregional control rate at 2 years will be recorded.</detailed_description>
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<criteria>resected welldifferentiated throid cancer with at least one high risk feature for locoregional recurrence medullary or anaplastic thyroid cancer, unresectable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>thyroid neoplasms</keyword>
	<keyword>intensity modulated radiation</keyword>
	<keyword>radiotherapy</keyword>
</DOC>